Cytokinetics appoints Robert E. Landry to Board of Directors, effective Feb 10, 2025

CYTOKINETICS INC

Robert E. Landry appointed as Class II director, term expiring at 2027 annual meeting.
Also appointed to Audit Committee; Board determined independent under SEC and Nasdaq rules.
Compensation includes $50k annual retainer, $12.5k Audit Committee retainer, and annual equity grant of $440k.
Received initial option grant of 25,538 shares with $700k grant date fair value, vesting over three years.
Standard indemnification agreement entered into; no other arrangements or transactions requiring disclosure.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Robert E. Landry

Director

CYTK · CYTOKINETICS INC

Effective: 2025-02-10
Filed: February 11, 2025, 6:59 PM ET

On February 10, 2025, (the “ Effective Date ”), the Board of Directors (the “ Board ”) of Cytokinetics, Incorporated (the “ Company ”) appointed, upon the recommendation of the Nominating and Governance Committee of the Board, Robert E. Landry to fill a vacant Board seat and to serve as a Class II member of the Board with an initial term expiring at the Company’s 2027 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Robert E. Landry was appointed as Director at CYTOKINETICS INC.

Action: appointed
Role: Director

Exact text from the filing

On February 10, 2025, (the “ Effective Date ”), the Board of Directors (the “ Board ”) of Cytokinetics, Incorporated (the “ Company ”) appointed, upon the recommendation of the Nominating and Governance Committee of the Board, Robert E. Landry to fill a vacant Board seat and to serve as a Class II member of the Board with an initial term expiring at the Company’s 2027 annual meeting of stockholders.

View on SEC.gov

CYTOKINETICS INC filing history →

Source: SEC EDGAR

accession 0000950170-25-017458

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.